Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
The Secondary Objectives are:
1. To estimate symptom improvement rates at weeks 2 and 12
2. To estimate mean change from baseline in overall QoL scores using the FACT-L instrument and LCS score at Week 2, 4 and 12.
3. To estimate the proportion of patients exhibiting an LCS change of 7 points or more at weeks 2, 4 and 12.
4. Subgroup information of symptom improvement rate, QoL and disease-related symptom scores by gender, smoking status, smoking pattern, WHO performance, number of metastatic sites, female/never smokers and patients with COPD at week 2, week 4 and week 12.
Age
20–130
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients diagnosed with symptomatic, locally advanced or metastatic (stage IIIb/IV) NSCLC.
Patients who are positive for EGFR mutation
Patients with a prescription of EGFR-TKI as their first-line treatment
You may not be if
\- Involvement in any planning and/or conduct of the clinical trial.